


**PRODUCT: Dovitinib**

**ALTERNATE NAMES:** CHIR-258; CHIR 258; CHIR258; 1-amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one; (3Z)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one; TKI258; TKI-258; TKI 258; Multitargeted RTK inhibitor

**CATALOG #:** B1614-5, -25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>21</sub>H<sub>21</sub>FN<sub>6</sub>O

**MOLECULAR WEIGHT:** 392.43

**CAS NUMBER:** 405169-16-6

**APPEARANCE:** Solid

**SOLUBILITY:** DMSO (30 mg/mL) (76.44 mM)

**PURITY:** ≥99.5% by HPLC

**STORAGE:** Store at -20°C. Protect from air and light.

**DESCRIPTION:** Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC<sub>50</sub> of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC<sub>50</sub> of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

- ABT-869 (# 1615)
- Crizotinib (1934)
- R428 (# 9591)
- SU 6668 (1931)

**USAGE:** *FOR RESEARCH USE ONLY! Not to be used in humans*